Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Kurata K. et al, (2023), Blood cancer j, 13

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Kurata K. et al, (2023), Blood cancer j, 13

Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers.

Agarwal G. et al, (2022), Cancers (basel), 15

Prospective assessment of myeloma tumour burden and bone disease using DW-MRI and exploratory bone biomarkers

Agarwal G. et al, (2022), Hemasphere, 6, 777 - 778

Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival.

Whitburn J. et al, (2022), Sci adv, 8

Development of a mass cytometry-based toolkit to investigate myeloma therapeutic responses ex vivo

Gooding S. et al, (2022), Clinical lymphoma myeloma & leukemia, 22, S71 - S71

Prospective assessment of myeloma tumour burden and bone disease using DW-MRI and exploratory bone biomarkers

Agarwal G. et al, (2022), Clinical lymphoma myeloma & leukemia, 22, S59 - S59

Include forthcoming?